| Dana Lynne Casey, MD | |
|
101 Manning Drive Cb 7512, Chapel Hill, NC 27599-6007 | |
| (727) 798-3166 | |
| Not Available |
| Full Name | Dana Lynne Casey |
|---|---|
| Gender | Female |
| Speciality | Radiation Oncology |
| Experience | 9 Years |
| Location | 101 Manning Drive Cb 7512, Chapel Hill, North Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194110882 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of North Carolina Hospital | Chapel hill, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Unc Physicians And Associates | 0648181156 | 1656 |
News Archive
The Ikerbasque researcher Koen Vandenbroeck, who heads the Neurogenomiks laboratory which reports to the Achucarro centre and the UPV/EHU-University of the Basque Country, together with other national and international groups, has shown that a genetic variant in the 5q11 chromosome, which is associated with susceptibility to developing multiple sclerosis, greatly regulates a gene known as ANKRD55. ANKRD55 is a gene with an unknown function.
Microvisk Technologies, the developer of a handheld system to monitor the blood clotting status of patients taking the drug Warfarin, has raised £6 million through a rights issue to existing investors in an oversubscribed round. This is the third successful funding round for Microvisk, which has secured £10.5m in the past 12 months - the largest amount raised by a UK life science company**.
Three labs from the University of Pennsylvania have received $12.5 million from the National Institutes of Health (NIH) as part of its $143.8 million national grant program to challenge the scientific status quo with innovative ideas that have the potential to speed the translation of medical research into improved health for the American public.
AstraZeneca today announced that the US Food and Drug Administration has approved TAGRISSO (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
Unnecessary prostate cancer biopsies could be reduced by 60 percent thanks to new research from the University of East Anglia.
› Verified 1 days ago
| Entity Name | University Of North Carolina At Chapel Hill |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780669200 PECOS PAC ID: 0648181156 Enrollment ID: O20031105000359 |
News Archive
The Ikerbasque researcher Koen Vandenbroeck, who heads the Neurogenomiks laboratory which reports to the Achucarro centre and the UPV/EHU-University of the Basque Country, together with other national and international groups, has shown that a genetic variant in the 5q11 chromosome, which is associated with susceptibility to developing multiple sclerosis, greatly regulates a gene known as ANKRD55. ANKRD55 is a gene with an unknown function.
Microvisk Technologies, the developer of a handheld system to monitor the blood clotting status of patients taking the drug Warfarin, has raised £6 million through a rights issue to existing investors in an oversubscribed round. This is the third successful funding round for Microvisk, which has secured £10.5m in the past 12 months - the largest amount raised by a UK life science company**.
Three labs from the University of Pennsylvania have received $12.5 million from the National Institutes of Health (NIH) as part of its $143.8 million national grant program to challenge the scientific status quo with innovative ideas that have the potential to speed the translation of medical research into improved health for the American public.
AstraZeneca today announced that the US Food and Drug Administration has approved TAGRISSO (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
Unnecessary prostate cancer biopsies could be reduced by 60 percent thanks to new research from the University of East Anglia.
› Verified 1 days ago
| Entity Name | Smithfield Radiation Oncology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255360459 PECOS PAC ID: 6709835846 Enrollment ID: O20090210000776 |
News Archive
The Ikerbasque researcher Koen Vandenbroeck, who heads the Neurogenomiks laboratory which reports to the Achucarro centre and the UPV/EHU-University of the Basque Country, together with other national and international groups, has shown that a genetic variant in the 5q11 chromosome, which is associated with susceptibility to developing multiple sclerosis, greatly regulates a gene known as ANKRD55. ANKRD55 is a gene with an unknown function.
Microvisk Technologies, the developer of a handheld system to monitor the blood clotting status of patients taking the drug Warfarin, has raised £6 million through a rights issue to existing investors in an oversubscribed round. This is the third successful funding round for Microvisk, which has secured £10.5m in the past 12 months - the largest amount raised by a UK life science company**.
Three labs from the University of Pennsylvania have received $12.5 million from the National Institutes of Health (NIH) as part of its $143.8 million national grant program to challenge the scientific status quo with innovative ideas that have the potential to speed the translation of medical research into improved health for the American public.
AstraZeneca today announced that the US Food and Drug Administration has approved TAGRISSO (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
Unnecessary prostate cancer biopsies could be reduced by 60 percent thanks to new research from the University of East Anglia.
› Verified 1 days ago
| Entity Name | Johnston Radiation Oncology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578885406 PECOS PAC ID: 7012048838 Enrollment ID: O20100623000219 |
News Archive
The Ikerbasque researcher Koen Vandenbroeck, who heads the Neurogenomiks laboratory which reports to the Achucarro centre and the UPV/EHU-University of the Basque Country, together with other national and international groups, has shown that a genetic variant in the 5q11 chromosome, which is associated with susceptibility to developing multiple sclerosis, greatly regulates a gene known as ANKRD55. ANKRD55 is a gene with an unknown function.
Microvisk Technologies, the developer of a handheld system to monitor the blood clotting status of patients taking the drug Warfarin, has raised £6 million through a rights issue to existing investors in an oversubscribed round. This is the third successful funding round for Microvisk, which has secured £10.5m in the past 12 months - the largest amount raised by a UK life science company**.
Three labs from the University of Pennsylvania have received $12.5 million from the National Institutes of Health (NIH) as part of its $143.8 million national grant program to challenge the scientific status quo with innovative ideas that have the potential to speed the translation of medical research into improved health for the American public.
AstraZeneca today announced that the US Food and Drug Administration has approved TAGRISSO (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
Unnecessary prostate cancer biopsies could be reduced by 60 percent thanks to new research from the University of East Anglia.
› Verified 1 days ago
| Entity Name | Rex Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144248683 PECOS PAC ID: 0840109864 Enrollment ID: O20140613001181 |
News Archive
The Ikerbasque researcher Koen Vandenbroeck, who heads the Neurogenomiks laboratory which reports to the Achucarro centre and the UPV/EHU-University of the Basque Country, together with other national and international groups, has shown that a genetic variant in the 5q11 chromosome, which is associated with susceptibility to developing multiple sclerosis, greatly regulates a gene known as ANKRD55. ANKRD55 is a gene with an unknown function.
Microvisk Technologies, the developer of a handheld system to monitor the blood clotting status of patients taking the drug Warfarin, has raised £6 million through a rights issue to existing investors in an oversubscribed round. This is the third successful funding round for Microvisk, which has secured £10.5m in the past 12 months - the largest amount raised by a UK life science company**.
Three labs from the University of Pennsylvania have received $12.5 million from the National Institutes of Health (NIH) as part of its $143.8 million national grant program to challenge the scientific status quo with innovative ideas that have the potential to speed the translation of medical research into improved health for the American public.
AstraZeneca today announced that the US Food and Drug Administration has approved TAGRISSO (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
Unnecessary prostate cancer biopsies could be reduced by 60 percent thanks to new research from the University of East Anglia.
› Verified 1 days ago
| Entity Name | Rex Radiation Oncology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164880571 PECOS PAC ID: 5294025441 Enrollment ID: O20160601000693 |
News Archive
The Ikerbasque researcher Koen Vandenbroeck, who heads the Neurogenomiks laboratory which reports to the Achucarro centre and the UPV/EHU-University of the Basque Country, together with other national and international groups, has shown that a genetic variant in the 5q11 chromosome, which is associated with susceptibility to developing multiple sclerosis, greatly regulates a gene known as ANKRD55. ANKRD55 is a gene with an unknown function.
Microvisk Technologies, the developer of a handheld system to monitor the blood clotting status of patients taking the drug Warfarin, has raised £6 million through a rights issue to existing investors in an oversubscribed round. This is the third successful funding round for Microvisk, which has secured £10.5m in the past 12 months - the largest amount raised by a UK life science company**.
Three labs from the University of Pennsylvania have received $12.5 million from the National Institutes of Health (NIH) as part of its $143.8 million national grant program to challenge the scientific status quo with innovative ideas that have the potential to speed the translation of medical research into improved health for the American public.
AstraZeneca today announced that the US Food and Drug Administration has approved TAGRISSO (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
Unnecessary prostate cancer biopsies could be reduced by 60 percent thanks to new research from the University of East Anglia.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dana Lynne Casey, MD 101 Manning Drive, Cb #7512, Chapel Hill, NC 27599 Ph: (984) 974-0400 | Dana Lynne Casey, MD 101 Manning Drive Cb 7512, Chapel Hill, NC 27599-6007 Ph: (727) 798-3166 |
News Archive
The Ikerbasque researcher Koen Vandenbroeck, who heads the Neurogenomiks laboratory which reports to the Achucarro centre and the UPV/EHU-University of the Basque Country, together with other national and international groups, has shown that a genetic variant in the 5q11 chromosome, which is associated with susceptibility to developing multiple sclerosis, greatly regulates a gene known as ANKRD55. ANKRD55 is a gene with an unknown function.
Microvisk Technologies, the developer of a handheld system to monitor the blood clotting status of patients taking the drug Warfarin, has raised £6 million through a rights issue to existing investors in an oversubscribed round. This is the third successful funding round for Microvisk, which has secured £10.5m in the past 12 months - the largest amount raised by a UK life science company**.
Three labs from the University of Pennsylvania have received $12.5 million from the National Institutes of Health (NIH) as part of its $143.8 million national grant program to challenge the scientific status quo with innovative ideas that have the potential to speed the translation of medical research into improved health for the American public.
AstraZeneca today announced that the US Food and Drug Administration has approved TAGRISSO (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
Unnecessary prostate cancer biopsies could be reduced by 60 percent thanks to new research from the University of East Anglia.
› Verified 1 days ago
Joseph Kt Lee, MD Radiology Medicare: Medicare Enrolled Practice Location: 101 Manning Dr, Chapel Hill, NC 27599 Phone: 919-966-4131 | |
Dr. Maureen Pearl Kohi, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 101 Manning Dr, Chapel Hill, NC 27514 Phone: 984-974-1000 | |
Matthew Mauro, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 101 Manning Dr, Chapel Hill, NC 27599 Phone: 919-966-8596 Fax: 919-843-5515 | |
Kenneth Lury, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 101 Manning Dr, Chapel Hill, NC 27599 Phone: 919-966-8596 Fax: 919-843-5515 | |
Dr. Rachel Ann Hitt, MD MPH Radiology Medicare: Accepting Medicare Assignments Practice Location: 101 Manning Dr, Chapel Hill, NC 27514 Phone: 919-966-4292 | |
Steven H Edelman, MD Radiology Medicare: Medicare Enrolled Practice Location: Unc-ch Dept Of Radiology W2108a Old Clinic Cb#7510, Chapel Hill, NC 27599 Phone: 919-966-9047 Fax: 919-843-8740 | |
Dr. Lee David Bell Jr., M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 101 Manning Dr, Chapel Hill, NC 27514 Phone: 919-966-1072 |